Product Specifications:
Item#1024: Recombinant HIV-1 MN Envelope Glycoprotein gp160 (Baculovirus)
Concentration: See vial
Mass/vial:100ug
Diluent: PBS
Purity: >90%
Stabilizer: None
Preservative: None
Storage: -75°C
Physical State: Frozen Liquid
Stability: At least 24 months at -75°C.
Applications: Human diagnostics, CD4 binding, Drug screening, Human T-cell CD4 studies.
Description: Gene cloned from T-cell-tropic HIV-1 MN strain and the full length recombinant envelope gp160 glycoprotein produced in the Baculovirus Expression System.
Purification:This protein is purified by immuno-affinity chromatography to >95% purity as determined by SDS-PAGE, reduced.
Specificity: This protein binds to murine monoclonal antibodies of defined epitope specificity and HIV-1 converted human serum polyclonal antibodies in ELISA and Western ELISA.
Biological Activity: Determination pending.
Applications and Instructions for use:
Recommended concentrations for use are approximate values. A dose dependent response assay should be performed to determine the optimal concentration for use in specific applications.
ELISA and Western ELISA require 10-100ng protein depending on the nature and affinity of the detection reagent. Human serum polyclonal antibodies yield titers of 1:1000 or greater at 10-100ng of immobilized protein under standard ELISA conditions.
Related Clinical Trials
Official Title: | A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults |
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults
Intervention:
Biological: MN rgp120/HIV-1 and A244 rgp120/HIV-1, QS-21, rgp120/HIV-1MN
Group 1: low-dose MN rsgp120/HIV-1 plus QS-21 (13 volunteers). Group 2: high-dose MN rsgp120/HIV-1 plus QS-21 (13 volunteers). Group 3: AIDSVAX B/E (injection contains each of the two vaccine components, HIV-1 MN rgp120 and A244 rgp120/HIV-1) plus QS-21 plus alum (13 volunteers).
Group 4: high-dose MN rgp120/HIV-1 plus QS-21 plus alum (13 volunteers). Group 5: placebo plus QS-21 (8 volunteers). Volunteers will be closely monitored after each immunization and followed for a minimum of 12 months after the initial immunization.
Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector.
The development of a vaccine against human immunodeficiency virus-1 (HIV-1) capable of inducing broad humoral and cellular responses at both the systemic and mucosal levels will be critical for combating the global AIDS epidemic. We previously demonstrated the ability of Newcastle disease virus (NDV) as a vaccine vector to express oligomeric Env protein gp160 and induce potent humoral and mucosal immune responses. In the present study, we used NDV vaccine strain LaSota as a vector to compare the biochemical and immunogenic properties of vector-expressed gp160, gp120, and two versions of gp140 (a derivative of gp160 made by deleting the transmembrane and cytoplasmic domains), namely: gp140L.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
本试验阳性结果主要见于下列几种情况:
1.自身免疫性贫血,(IgG)型引起的溶血性贫血,本试验直接反应常呈强阳性,间接反应大多阴性,但亦可阳性。
2.药物诱发的免疫性溶血性贫血①α-甲基多巴型:直接及间接反应均阳性。②青霉素型:直接反应阳性,间接反应阴性,以上二型如以正常红细胞先与有关药物于37℃培育后再加病人血清、间接反应均为阳性。③福阿亭型:(奎宁等药物)抗体通常为IgM,偶有IgG型者,直接反应为阳性,间接反应阴性,但如用IgG抗血清做试剂则结果大部分均为阴性,但如培育时加入新鲜正常人血清(供应补体)则结果为阳性。
3.冷凝集素综合征直接反应阳性,间接反应阴性(试验需在37℃下进行)由于本病红细胞膜附着的是补体C4和C3而不是IgG或IgM,如果用抗IgG或抗IgM抗血清做试验时,则结果阴性,如以抗补体的抗血清做试验则直接反应阳性。
4.新生儿同种免疫溶血病,因Rh血型不合所致溶血病,直接及间接反应均强阳性,持续数周、换血输血后数天内可变为阴性,由于“ABO”血型不合引起的溶血病,结果常为阴性或弱阳性。
5.红细胞血型不合引起的输血反应,ABO或Rh血型不合输血,供者的红细胞被受者的血型抗体致敏,在供者被致敏的红细胞完全破坏以前,直接反应阳性,Rh阴性者如过去不曾接受过Rh阳性者的血或曾妊娠胎儿为Rh阳性者,间接反应阳性,如无上述接触,第一次输血后(Rh阳性的血),数天之内间接反应也会变为阳性。
6.其它在传染性单核细胞增多症、SLE、恶性淋巴瘤、慢性淋巴细胞白血病、癌肿、铅中毒、结节性动脉周围炎、EVan氏综合征等,病人直接反应亦可阳性,阵发性寒冷性血红蛋白尿症患者中,急性发作后用抗补体血清做试验直接反应常为阳性。展开
抗人球蛋白试验,又称Coombs’试验,是诊断自身免疫性溶血性贫血(AIHA)的重要依据。
正常人直接与间接试验均为阴性,Coombs’试验阴性有时并不能排除AIHA